Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Scancell receives European patent protection for immunotherapy platform

The patent protects a new class of cancer vaccines rolling off the Moditope platform
word patent spelled out in building blocks
The company is looking to extent patent protection internationally

Scancell Holdings PLC (LON:SCLP) said the European Patent Office has "granted broad protection" for the company's Moditope immunotherapy platform, which comes into effect from June 13.

It covers the company's pipeline of Moditope-derived vaccines. Counterparts to thpatent have been filed in Australia, Brazil, Canada, China, Hong Kong, Japan, South Korea, South Africa and the US, the firm added.

"This is a key patent for Scancell and endorses our work in identifying a new class of cancer vaccine capable of inducing potent immune responses to stress-induced post-translational modifications (siPTM), in this case, through citrullination of cellular proteins," said chief scietific officer,  Professor Lindy Durrant.

Well positioned

"We are now well positioned to develop a pipeline of new Moditope therapies with the potential to address the unmet need across a broad range of hard-to-treat cancers including ovarian, triple negative breast cancer and sarcoma."

First-in-man trials with Modi-1, which combines Moditope peptides with an ultra-efficient substance called an adjuvant that enhances the body's immune response, are due to start in the first half of next year.

 

View full SCLP profile View Profile

Scancell Holdings Plc Timeline

Related Articles

pills
July 25 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
1521490126_shutterstock_234586750.jpg
March 19 2018
The group has received key permits to allow cannabis - flowers and oils - to be imported into Australia from Aurora Cannabis Inc
immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use